COMBINATIONAL THERAPY ENHANCES ANTITUMOR ACTIVITY IN TUMORS RESISTANT TO IRINOTECAN TREATMENT IN A PRECLINICAL CRC MODEL

被引：0
|
作者：
Greene, J. L. [1 ]
Bagby, S. [1 ]
Messersmith, W. [1 ]
Aracaroli, J. [1 ]
机构：
[1] Univ Colorado, Aurora, CO USA
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2015年 / 63卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
421
引用
收藏
页码：210 / 210
页数：1
相关论文
共 50 条
  • [1] Preclinical Antitumor Activity of Cabazitaxel, a Semisynthetic Taxane Active in Taxane-Resistant Tumors
    Vrignaud, Patricia
    Semiond, Dorothee
    Lejeune, Pascale
    Bouchard, Herve
    Calvet, Loreley
    Combeau, Cecile
    Riou, Jean-Francois
    Commercon, Alain
    Lavelle, Francois
    Bissery, Marie-Christine
    CLINICAL CANCER RESEARCH, 2013, 19 (11) : 2973 - 2983
  • [2] Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice
    Stewart, CF
    Leggas, M
    Schuetz, JD
    Panetta, JC
    Cheshire, PJ
    Peterson, J
    Daw, N
    Jenkins, JJ
    Gilbertson, R
    Germain, GS
    Harwood, FC
    Houghton, PJ
    CANCER RESEARCH, 2004, 64 (20) : 7491 - 7499
  • [3] Pharmacokinetics, tumor accumulation and antitumor activity of nanoliposomal irinotecan following systemic treatment of intracranial tumors
    Noble, Charles O.
    Krauze, Michal T.
    Drummond, Daryl C.
    Forsayeth, John
    Hayes, Mark E.
    Beyer, Janine
    Hadaczek, Piotr
    Berger, Mitchel S.
    Kirpotin, Dmitri B.
    Bankiewicz, Krystof S.
    Park, John W.
    NANOMEDICINE, 2014, 9 (14) : 2099 - 2108
  • [4] The novel ATM inhibitor (AZ31) enhances antitumor activity in patient derived xenografts that are resistant to irinotecan monotherapy
    Greene, Justin
    Nguyen, Anna
    Bagby, Stacey M.
    Jones, Gemma N.
    Tai, Wm.
    Quackenbush, Kevin S.
    Schreiber, Anna
    Messersmith, Wells A.
    Devaraj, Kalpana M.
    Blatchford, Patrick
    Eckhardt, S. Gail
    Cadogan, Elaine B.
    Hughes, Gareth D.
    Smith, Aaron
    Pitts, Todd M.
    Arcaroli, John J.
    ONCOTARGET, 2017, 8 (67) : 110904 - 110913
  • [5] Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical Model
    Huang, Jiao-Ren
    Lee, Mei-Hsien
    Li, Wen-Shan
    Wu, Han-Chun
    CANCERS, 2019, 11 (03):
  • [6] Natural killer cell therapy potentially enhances the antitumor effects of bevacizumab plus irinotecan in a glioblastoma mouse model
    Tran, Thi-Anh-Thuy
    Kim, Young-Hee
    Duong, Thi-Hoang-Oanh
    Thangaraj, JayaLakshmi
    Chu, Tan-Huy
    Jung, Shin
    Kim, In-Young
    Moon, Kyung-Sub
    Kim, Young-Jin
    Lee, Tae-Kyu
    Lee, Chul Won
    Yun, Hyosuk
    Lee, Je-Jung
    Lee, Hyun-Ju
    Lee, Kyung-Hwa
    Jung, Tae-Young
    FRONTIERS IN IMMUNOLOGY, 2023, 13
  • [7] Antitumor activity and pharmacolkinetics of a novel PEGylated irinotecan in irinotecan-resistant colorectal tumours implanted in mice
    Eldon, M. A.
    Antonian, L.
    Staschen, C. M.
    Viegas, T. X.
    Bentley, M.
    Singhal, A.
    EJC SUPPLEMENTS, 2007, 5 (04): : 114 - 114
  • [8] NHS-IL12 and bintrafusp alfa combination therapy enhances antitumor activity in preclinical cancer models
    Xu, Chunxiao
    Marelli, Bo
    Qi, Jin
    Qin, Guozhong
    Yu, Huakui
    Wang, Hong
    Jenkins, Molly H.
    Lo, Kin-Ming
    Lan, Yan
    TRANSLATIONAL ONCOLOGY, 2022, 16
  • [9] Evaluation of PTEN expression in colorectal cancer (CRC) metastases (mets) and in primary tumors as predictors of activity of cetuximab plus irinotecan treatment
    Loupakis, F.
    Pollina, L.
    Stasi, I.
    Masi, G.
    Funel, N.
    Scartozzi, M.
    Petrini, I.
    Santini, D.
    Cascinu, S.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Preclinical antitumor activity and pharmacokinetics of irinotecan (CPT-11) in tumor-bearing mice
    Bissery, MC
    Vrignaud, P
    Lavelle, F
    Chabot, GG
    CAMPTOTHECINS: FROM DISCOVERY TO THE PATIENT, 1996, 803 : 173 - 180
12345